News | Molecular Imaging | June 26, 2015

Navidea Reports Manocept Study Results in Rheumatoid Arthritis Radiotracer

Findings indicate higher concentration of CD206 receptor in patients with RA

Navidea, Manocept, CD206 receptor, rheumatoid arthritis

June 26, 2015 - Navidea Biopharmaceuticals announced that results from several pre-clinical Manocept studies in rheumatoid arthritis (RA) were presented at the EULAR 2015 European Congress of Rheumatology in Rome, Italy from June 10-13, 2015.  The results of studies, led by Wael Jarjour, M.D., Thomas J. Rosol, Ph.D., and Larry S. Schlesinger, M.D., of The Ohio State University Wexner Medical Center, highlighted the potential of CD206-targeting Manocept constructs to detect immune-mediated inflammation in RA ,which could be used diagnostically to monitor therapeutic efficacy or as a potential therapeutic platform.

"Diagnosing patients with RA can be challenging because the commonly used laboratory assays are negative in 20 percent of affected patients. Additionally, there are limited reliable tools to assess disease activity and guide therapy in patients with difficult clinical presentations," said  Jarjour, associate professor and director, Division of Rheumatology & Immunology, The Ohio State University Wexner Medical Center. "We believe that Manocept-targeting of macrophages shows promise in detecting immune-mediated inflammation in RA and could potentially be used diagnostically or to monitor therapeutic efficacy in patients."

The oral presentation entitled, " Manocept, a Derivative of FDA-Approved 99mTc-Tilmanocept, Exhibits Diagnostic Potential by Specifically Identifying Macrophages in Rheumatoid Arthritis: A Novel Application of an Existing Drug," ( DOI : 10.1136/annrheumdis-2015-eular. 4876) showed results from synovial fluid and tissue acquired from RA patients for comparison to normal frozen archival tissue and synovial tissue procured from patients with osteoarthritis (OA). Tissues were probed with Manocept-Cy3, DAPI nuclear stain, and anti CD206-cyanine. Mononuclear cells were isolated from RA synovial fluid and analyzed by flow cytometry. Results demonstrated that archival synovial tissue and synovial fluid obtained from patients diagnosed with RA contain a significant population of macrophages that express high levels of the CD206 receptor. It was shown that these macrophages strongly co-localize Manocept-Cy3 and CD206 receptors. The degree of macrophage infiltration in tissue from healthy or osteoarthritic patients was significantly lower than in RA tissues. 

Additionally in an in vivo animal study, arthritis was induced in mice and was followed with intravenous injection of Manocept-Cy3 and epi-fluorescent imaging. Imaging results indicated that Manocept can be detected in inflamed joints in an in vivo animal model of RA.

For more information:

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
Overlay Init